Arcus reports Phase 2 EDGE-Gastric interim data: median PFS 12.9 months, ORR 58.5% in upper GI cancers

Arcus Biosciences, Inc.

Median PFS of 12.9 months (95% CI 9.8–13.8) across 41 patients in the domvanalimab+zimberelimab+chemo arm.
Confirmed ORR 58.5%, with 3 complete responses and median DOR of 12.4 months (95% CI 9.9–NE).
PD-L1-high subgroup (TAP ≥5%) showed median PFS 13.8 months and ORR 68.8% (n=16).
No unexpected safety signals; infusion-related reactions in 19.5% of subjects, mostly chemotherapy-related.
Data cutoff March 12, 2024; results posted to company website on June 2, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.